Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03755791
Title Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Exelixis
Indications

hepatocellular carcinoma

Therapies

Cabozantinib

Sorafenib

Atezolizumab + Cabozantinib

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.